Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA.
Werner J. Struss(University of British Columbia), Alexander W. Wyatt(University of British Columbia), Kevin Beja(University of British Columbia), Matti Annala(Tampere University), Gillian Vandekerkhove(University of British Columbia), Martin Gleave(University of British Columbia), Amanda Wong(University of British Columbia), Evan W. Warner(Guardant (United States)), Kim N.(Asian Institute of Technology)
Cited by 3
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Antisense therapy for cancer
|Nature reviews. Cancer|2005|399